TuHURA Biosciences, Inc. Common Stock
HURATuHURA Biosciences, Inc. is a biotechnology company focused on developing innovative therapies in the cancer treatment space. The company emphasizes research and development in immuno-oncology and targeted therapies, aiming to improve outcomes for patients with various cancer types.
Company News
The Merkel cell carcinoma market is expected to grow significantly between 2025-2034, driven by rising global incidence, increased awareness, and innovative treatment developments like immunotherapies and targeted therapies.
TuHURA Biosciences advanced its immuno-oncology pipeline in Q2 2025, launching a Phase 3 trial for IFx-2.0 in Merkel cell carcinoma and completing the Kineta acquisition. The company raised $15.5 million in equity financing to support ongoing clinical development.
Halper Sadeh LLC is investigating potential violations of federal securities laws and/or breaches of fiduciary duties to shareholders related to the proposed sales and mergers of The Shyft Group, MoneyLion Inc., TuHURA Biosciences, Inc., and Kineta, Inc.
Halper Sadeh LLC is investigating several companies, including MoneyLion Inc., Patterson Companies, Inc., TuHURA Biosciences, Inc., and Kineta, Inc., for potential violations of securities laws and breaches of fiduciary duties to shareholders related to proposed mergers and acquisitions.
The M&A Class Action Firm is investigating the proposed merger between Kineta, Inc. (OTC: KANT) and TuHURA Biosciences, Inc. The firm is looking into the terms of the agreement, where TuHURA would acquire the rights to Kineta's KVA12123 antibody.
